Taurus Meds review

What it is

Taurus Meds (Taurus Medical, Inc., a Delaware corporation) is a direct-to-consumer telehealth platform for testosterone replacement therapy, ED and peptides — explicitly not a GLP-1 or weight-loss service. Its testosterone line covers injectable testosterone cypionate, oral enclomiphene and a testosterone gel on a $149 monthly all-inclusive subscription after a $49 promotional intake, listed against a $129 list price. Its peptide line is three products: sermorelin, NAD⁺ injection and glutathione, each displaying "$179 $79/mo". Clinical care runs through OpenLoop Health, with LabCorp and Quest handling the baseline blood draw.

How it works

Video-gated and lab-anchored on the testosterone side, which is the correct shape for the therapy. The intake bundles an at-home blood test with a short clinician video consultation before anything is prescribed, and the monthly fee is stated to cover the visit, the medication and shipping with no membership on top. The disclosure stack is above average for the segment: OpenLoop Health is named as the partner clinician network and is a known multi-brand telehealth operator, four compounding pharmacies are named verbatim in the Terms — RedRock, Health Warehouse, Precision Compounding and Triad Rx — and two national lab chains are named. HIPAA and HITECH compliance are explicitly affirmed. Three things sit against it and all three are worth resolving before purchase. The refund position contradicts itself: the product page advertises a full refund within 90 days while the Terms state that all sales on shipped medications are final and that blood work is non-refundable, with the guarantee itself qualified "minus lab and pharmacy fees" — which appears to exclude most of what you paid. No state availability is published. And the registered address is a Delaware private mailbox rather than a working office, with support hours and a phone number unlisted.

Pricing transparency

Clean on one side of the business and not usable on the other. Testosterone is a flat $149 a month stated as all-inclusive — the visit, the medication and shipping — after a $49 promotional intake against a $129 list price, with the same monthly figure applying across injectable cypionate, oral enclomiphene and topical gel. A single flat number covering oversight and medication is a genuinely good structure and it is what we publish for its TRT card. Its peptide shelf is a different matter. Sermorelin, NAD⁺ injection and glutathione all currently display "$179 $79/mo", a promotional rate against a struck-through list price with no stated duration — and $79 is $50 below the promotional figure the same three products carried a fortnight earlier. Three chemically unrelated molecules at one price, moving that quickly, is a marketing position rather than a rate you can plan around, so we publish no floor on the peptide or NAD⁺ boards. Its ED product is priced separately from around $13 per dose with ingredients not disclosed before prescription. Exact medication strengths are not published anywhere before a prescribing decision.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Four compounding pharmacies are named in the Terms, which is meaningful traceability, and compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the two halves of this menu are separated by a very wide gap. Testosterone replacement has a large randomised safety base behind it, and it requires ongoing haematocrit, PSA and testosterone monitoring — a bundled at-home baseline test is the right start, and what is not stated is how often it repeats. Enclomiphene raises endogenous testosterone rather than replacing it, and is not an FDA-approved product in that form. The peptide side is thinner: sermorelin is a GHRH analogue with a real, well-described mechanism and thin long-term human outcome data; injected NAD⁺ has no controlled human outcome trials at all, with the oral precursors NR and NMN being the forms that carry human data and raise a blood level; and injectable glutathione has essentially no controlled human outcome data behind the antioxidant and energy claims made for it. Its product cards also repeat one injection claim verbatim under an oral sermorelin item, which is a copy-paste error rather than a claim about the product. Individual results vary.

Pros and watch-outs

The evidence behind what Taurus Meds prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

• TRT and Hematocrit: Why Testosterone Thickens the Blood, and What to Do About It

  Erythrocytosis is the most common lab change on testosterone therapy — predictable, route-dependent, and manageable with monitoring.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

How Taurus Meds compares

A few alternatives worth a look, depending on what you’re optimizing for.

• SHStealth Health

  People who want to compare injectable NAD⁺ against oral nicotinamide riboside on one menu

  See Stealth Health →
• RRRyze Rx

  Shoppers who want NAD⁺ on the same platform as TRT and will confirm every figure in writing

  See Ryze Rx →
• PRPrescribedRX

  Men who want to know before intake whether their state is excluded

  See PrescribedRX →